HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Apr.1)- Lower Budget of Public Hospitals, IPO Environment, Impatient Market

Pre-IPO Betters Medical Investment Holdings - The Industry, the Business and the Concerns

Health And Happiness (H&H) (1112.HK) - High Bankruptcy Risk Together with Gloomy Prospects

Akeso Biopharma Inc (9926.HK) - Caution Is Advised Until Sufficient Financing Is Secured

Hutchmed China Ltd (13.HK/HCM.US) - Big but Not Strong

CSPC Pharmaceutical Group (1093.HK) - Conservative About the Business Transformation Outlook

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Guanze Intelligent Medical Information Industry Holding / Equity Capital Markets

Guanze Intelligent Medical Information Industry Holding (GIM HK)

Guanze Intelligent Medical Information Industry Holding

<ul>
<li>Guanze relies heavily on sale of medical imaging film products in Shandong Province, and occupies a leading market position in Shandong based on its accumulation in local networks and resources.</li>
<li>However, the market size in Shandong is limited, with growth ceiling.With the trend of new technology and unproven ability to expand nationwide,there's a risk of being eliminated in long term.</li>
<li>In this context, Guanze could face a lot of challenges and uncertainties. Therefore, we are conservative about the Company’s outlook at the current stage.</li>
</ul>


Guanze relies heavily on sale of medical imaging film products in Shandong Province, and occupies a leading market position in Shandong based on its accumulation in local networks and resources.
However, the market size in Shandong is limited, with growth ceiling.With the trend of new technology and unproven ability to expand nationwide,there's a risk of being eliminated in long term.
In this context, Guanze could face a lot of challenges and uncertainties. Therefore, we are conservative about the Company’s outlook at the current stage.


Pre-IPO Guanze Intelligent Medical Information Industry - Advantages in Shandong Cannot Hide Worries